Immune tolerance in hemophilia can be modulated by B cell activating factor

A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A. Hemophilia is the most common severe inherited bleeding disorder in men. The disease affects 1 in 10,000 males worldwide and results from deficiency of blood clotting factor VIII (FVIII). […]

Read more

Vaccines Won’t Protect Millions of Patients With Weakened Immune Systems

Many cannot produce enough infection-fighting cells to fend off the coronavirus. But researchers are testing one therapy that may help: monoclonal antibodies. By Apoorva Mandavilli For more than a year, Dr. Andrew Wollowitz has mostly been cloistered inside his home in Mamaroneck, N.Y. As chief of emergency medicine at Montefiore Medical Center in the Bronx, Dr. Wollowitz, 63, was eager […]

Read more

Antibody tests, even rapid finger pricks, are effective COVID-19 screening tools

New findings from a Michigan Medicine study reveal that antibody testing is predictive of prior COVID-19 infection, and rapid screening methods – even from finger pricks – are effective testing tools. Researchers analyzed antibody tests conducted on more than 500 subjects in patient care settings. They found that people who had COVID, including those with mild symptoms, produced antibodies. "For […]

Read more

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected hundreds of millions worldwide since its emergence more than a year ago. The virus has also been mutating throughout the pandemic, with several […]

Read more

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. The team showed that one full-length antibody and two antibody domains each effectively neutralized pseudotyped virus containing key mutations found within the B.1.1.7 […]

Read more

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of […]

Read more

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19). The team says one dose of the vaccine induced a much stronger antibody response against the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – […]

Read more

Research demonstrates multivalent nanobodies overcome SARS-CoV-2 variant mutations

Since the start of the COVID-19 (coronavirus disease 2019) pandemic in late December 2019, the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of this disease has caused more than 2.6 million deaths worldwide from over 117 million reported infections. However, as new vaccines are administered against the ancestral strain, many mutated variants of the virus are emerging across […]

Read more

Single-dose of BNT162b2 vaccine may not be protective without prior SARS-CoV-2 infection

Vaccine rollouts in many countries are bringing hope that the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), will come to an end in the foreseeable future. Several vaccines have shown high protective efficacy against SARS-CoV-2 infection or severe disease. Study: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose […]

Read more

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Austria was observed in the Ski resort Ischgl in early March 2020. Later, the virus spread across Austria and other countries in Northern Europe. Researchers conducted a cross-sectional study to gauge the seroprevalence of SARS-CoV-2 in the population, as measured in the blood serum. They found […]

Read more
1 2 3